Katrina Goddard, PhD, is a genetic epidemiologist who focuses on public health genomics and the translation of genomic applications into clinical practice. She has directed or collaborated on over 25 federally funded research studies and has held numerous leadership positions on national research consortia.
Through a variety of studies, Dr. Goddard has demonstrated the capacity within the translational research setting to link patient characteristics and genomic test orders and results with utilization and outcomes. She is the principal investigator on the CHARM study in the National Human Genome Research Institute’s Clinical Sequencing Evidence-Generating Research (CSER) consortium, which has an overarching goal of investigating the integration of genome-scale sequencing into clinical care for diverse and medically underserved individuals.
As the founding director for the NW Biobank, Dr. Goddard initiated and established the infrastructure for a repository of blood and tissue samples linked to the comprehensive electronic medical records of Kaiser Permanente Northwest members. She has also contributed to knowledge synthesis products that have far-reaching impact for numerous national organizations. She plays key roles in the NIH-funded ClinGen Consortium, directing its Knowledge Synthesis Team—which provides systematic evidence summaries on the ClinGen website for the entire genomics community—and co-chairing the Actionability Working Group. She has served on the board of directors of both the American Society of Human Genetics and the International Genetic Epidemiology Society.
Dr. Goddard recently launched a National Cancer Institute-funded study, CONNECT, to develop a prospective U.S. cohort and to recruit 150,000-200,000 adult participants enrolled in integrated health care systems to study the causes of cancer and the means of its prevention.
Prior to joining CHR, Dr. Goddard was on the faculty at Case Western Reserve University in the Division of Genetic & Molecular Epidemiology. She received her PhD in biostatistics from the University of Washington and a BS in molecular biology from the University of Wisconsin-Madison.
Selected Current Publications
- A New Prospective U.S. Cohort Set within the Health Care System Institutions to Study Cancer—Connect (NCI)
- Cancer Health Assessments Reaching Many—CSER (NHGRI)
- Expert Curation and EHR Integration—ClinGen (NHGRI)
- Behl AS, Goddard KA, Flottemesch TJ, Veenstra D, Meenan RT, Lin JS, Maciosek MV. Cost-effectiveness analysis of screening for KRAS and BRAF mutations in metastatic colorectal cancer. J Natl Cancer Inst 2012 Dec 5;104(23):1785-95. PMCID: PMC3514165
- Feigelson HS, Zeng C, Pawloski PA, Onitilo AA, Richards CS, Johnson MA, Kauffman TL, Webster J, Nyirenda C, Alexander GL, Hwang C, Cross D, McCarty CA, Davis RL, Schwarzkopf D, Williams AE, Honda S, Daida Y, Kushi LH, Delate T, Goddard KA; CERGEN Study Team. Does KRAS testing in metastatic colorectal cancer impact overall survival? A comparative effectiveness study in a population-based sample. PLoS One 2014 May 1;9(5):e94977. PMCID: PMC4006772
- Cross D, Rahm AK, Kauffman T, Webster J, Le A, Fiegelson HS, Alexander G, Meier P, Onitilo A, Pawloski P, Williams A, Honda S, Daida Y, McCarty C, Goddard K. Underutilization of Lynch Syndrome screening in a multisite study of colorectal cancer patients. Genetics in Medicine 2013 Dec;15(12):933-40. PMCID: PMC3855589
- Goddard KAB, Whitlock EP, Berg JS, Williams MS, Webber EM, Webster JA, Lin JS, Schrader KA, Campos-Outcalt D, Offit K, Feigelson HS, Hollombe C. Description and pilot results from a novel method for evaluating return of incidental findings from next-generation sequencing technologies. Genet Med 2013 Sep;15(9):721-8. PMCID: PMC3927794
- Nelson HD, Fu R, Goddard K, Mitchell JP, Okinaka-Hu L, Pappas M, Zakher B. Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer: Systematic Review to Update the U.S. Preventive Services Task Force Recommendation [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2013 Dec. Report No.: 12-05164-EF-1.
- Lin JS, Webber EM, Beil TL, Goddard KA, Whitlock EP. Fecal DNA testing in screening for colorectal cancer in average-risk adults. Comparative Effectiveness Review No. 52. AHRQ Publication No. 12-EHC022-EF. Agency for Healthcare Research and Quality, Rockville, MD. February 2012.
- Webber EM, Kauffman TL, O’Connor E, Goddard KAB. Systematic review of the predictive effect of MSI status in colorectal cancer patients undergoing 5FU-based chemotherapy. BMC Cancer 2015 Mar 21;15:156. PMCID: PMC4376504
- Betsou F, Gunter E, Clements J, Desouza Y, Goddard KA, Guadagni F, Yan W, Skubitz A, Somiari S, Yeadon T, Chuaqui R. Identification of evidence-based biospecimen quality-control tools: A report of the International Society for Biological and Environmental Repositories (ISBER) Biospecimen Science Working Group. J Mol Diagn 2013 Jan;15(1):3-16.
- Goddard KAB, Smith KS, Chen C, McMullen C, Johnson C. Biobank recruitment: Motivations for non-participation. Biopreservation and Biobanking 2009 June;7(2):119-121. PMCID: PMC3205734
- Goddard KAB, Ziegler A, Wellek S. Adapting the logical basis of tests for Hardy-Weinberg equilibrium to the real needs of association studies in human and medical genetics. Genet Epidemiol 2009 Nov;33(7):569-80.